These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 31799889)

  • 1. A Japanese nationwide survey of 23-valent pneumococcal capsular polysaccharide vaccine (PPSV23) coverage among patients with chronic medical condition aged 50 and older.
    Kawakami K; Nakamura A; Wakana A; Folaranmi TA; Iino T
    Hum Vaccin Immunother; 2020 Jul; 16(7):1521-1528. PubMed ID: 31799889
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Japanese nationwide survey of 23-valent pneumococcal capsular polysaccharide vaccine (PPSV23) revaccination coverage rate among elderly adults aged 65 and older and physician's attitude.
    Nakamura A; Kawakami K; Wakana A; Folaranmi TA; Iino T
    Hum Vaccin Immunother; 2020 Sep; 16(9):2292-2299. PubMed ID: 32045317
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Factors associated with PPSV23 coverage among older adults in Japan: a nationwide community-based survey.
    Murakami Y; Kanazu S; Petigara T; Oba MS; Nishiwaki Y; Watanabe A
    BMJ Open; 2019 Jul; 9(7):e030197. PubMed ID: 31315877
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults 70 years of age and older previously vaccinated with 23-valent pneumococcal polysaccharide vaccine.
    Jackson LA; Gurtman A; Rice K; Pauksens K; Greenberg RN; Jones TR; Scott DA; Emini EA; Gruber WC; Schmoele-Thoma B
    Vaccine; 2013 Aug; 31(35):3585-93. PubMed ID: 23688527
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Persistence of antibodies 1 year after sequential administration of the 13-valent pneumococcal conjugate vaccine and the 23-valent pneumococcal polysaccharide vaccine in adults.
    Schmoele-Thoma B; van Cleeff M; Greenberg RN; Gurtman A; Jones TR; Sundaraiyer V; Gruber WC; Scott DA
    Hum Vaccin Immunother; 2019; 15(3):575-583. PubMed ID: 30648932
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pneumococcal vaccination coverages by age, sex and specific underlying risk conditions among middle-aged and older adults in Catalonia, Spain, 2017.
    Vila-Córcoles A; Ochoa-Gondar O; de Diego C; Satué E; Vila-Rovira A; Aragón M
    Euro Surveill; 2019 Jul; 24(29):. PubMed ID: 31339099
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Updated recommendations for prevention of invasive pneumococcal disease among adults using the 23-valent pneumococcal polysaccharide vaccine (PPSV23).
    ;
    MMWR Morb Mortal Wkly Rep; 2010 Sep; 59(34):1102-6. PubMed ID: 20814406
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Revaccination with 23-valent pneumococcal polysaccharide vaccine in the Japanese elderly is well tolerated and elicits immune responses.
    Kawakami K; Kishino H; Kanazu S; Toshimizu N; Takahashi K; Sterling T; Wang M; Musey L
    Vaccine; 2016 Jul; 34(33):3875-81. PubMed ID: 27265450
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sequential administration of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naïve adults 60-64 years of age.
    Greenberg RN; Gurtman A; Frenck RW; Strout C; Jansen KU; Trammel J; Scott DA; Emini EA; Gruber WC; Schmoele-Thoma B
    Vaccine; 2014 Apr; 32(20):2364-74. PubMed ID: 24606865
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of administering 13-valent pneumococcal conjugate vaccine in addition to 23-valent pneumococcal polysaccharide vaccine to adults with immunocompromising conditions.
    Cho BH; Stoecker C; Link-Gelles R; Moore MR
    Vaccine; 2013 Dec; 31(50):6011-21. PubMed ID: 24148572
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Correlation between family physician's direct advice and pneumococcal vaccination intention and behavior among the elderly in Japan: a cross-sectional study.
    Higuchi M; Narumoto K; Goto T; Inoue M
    BMC Fam Pract; 2018 Sep; 19(1):153. PubMed ID: 30185157
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vaccination pattern of the 23-valent pneumococcal polysaccharide vaccine (PPV23) in Hangzhou, China: a coverage and adverse events following immunization of different age groups.
    Liu Y; Xu Y; Wang J; Che X; Gu W; Du J; Zhang X; Zhang X; Jiang W; Chen J; An Z
    Hum Vaccin Immunother; 2021 Jan; 17(1):157-161. PubMed ID: 32530728
    [No Abstract]   [Full Text] [Related]  

  • 13. Immunogenicity of simultaneous versus sequential administration of a 23-valent pneumococcal polysaccharide vaccine and a quadrivalent influenza vaccine in older individuals: A randomized, open-label, non-inferiority trial.
    Nakashima K; Aoshima M; Ohfuji S; Yamawaki S; Nemoto M; Hasegawa S; Noma S; Misawa M; Hosokawa N; Yaegashi M; Otsuka Y
    Hum Vaccin Immunother; 2018; 14(8):1923-1930. PubMed ID: 29561248
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pneumococcal conjugate vaccine triggers a better immune response than pneumococcal polysaccharide vaccine in patients with chronic lymphocytic leukemia A randomized study by the Swedish CLL group.
    Svensson T; Kättström M; Hammarlund Y; Roth D; Andersson PO; Svensson M; Nilsson I; Rombo L; Cherif H; Kimby E
    Vaccine; 2018 Jun; 36(25):3701-3707. PubMed ID: 29748028
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pneumococcal vaccination coverages among low-, intermediate-, and high-risk adults in Catalonia.
    Vila-Corcoles A; Ochoa-Gondar O; Hospital I; de Diego C; Satué E; Bladé J; Ansa X; Guzmán JA; Salsench E; Ramos F
    Hum Vaccin Immunother; 2016 Nov; 12(11):2953-2958. PubMed ID: 27454779
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pneumococcal vaccine coverage in Japan among patients with a history of splenectomy: Results of a retrospective administrative database study.
    Yamada M; Li M; Iino T
    Vaccine; 2021 May; 39(19):2692-2697. PubMed ID: 33865627
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevention of pneumococcal disease among infants and children - use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine - recommendations of the Advisory Committee on Immunization Practices (ACIP).
    Nuorti JP; Whitney CG;
    MMWR Recomm Rep; 2010 Dec; 59(RR-11):1-18. PubMed ID: 21150868
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 13-valent pneumococcal conjugate vaccine (PCV13) is immunogenic and safe in children 6-17 years of age with sickle cell disease previously vaccinated with 23-valent pneumococcal polysaccharide vaccine (PPSV23): Results of a phase 3 study.
    De Montalembert M; Abboud MR; Fiquet A; Inati A; Lebensburger JD; Kaddah N; Mokhtar G; Piga A; Halasa N; Inusa B; Rees DC; Heath PT; Telfer P; Driscoll C; Al Hajjar S; Tozzi A; Jiang Q; Emini EA; Gruber WC; Gurtman A; Scott DA
    Pediatr Blood Cancer; 2015 Aug; 62(8):1427-36. PubMed ID: 25810327
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness of 23-Valent Pneumococcal Polysaccharide Vaccine against Invasive Pneumococcal Disease in Adults, Japan, 2013-2017.
    Shimbashi R; Suzuki M; Chang B; Watanabe H; Tanabe Y; Kuronuma K; Oshima K; Maruyama T; Takeda H; Kasahara K; Fujita J; Nishi J; Kubota T; Tanaka-Taya K; Matsui T; Sunagawa T; Oishi K;
    Emerg Infect Dis; 2020 Oct; 26(10):2378-2386. PubMed ID: 32946721
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Uptake of pneumococcal polysaccharide vaccination among working-age adults with underlying medical conditions, United States, 2009.
    Lu PJ; Nuorti JP
    Am J Epidemiol; 2012 Apr; 175(8):827-37. PubMed ID: 22403807
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.